Vogenx (VOGX)
Develops an oral SGLT1 inhibitor for post-bariatric hypoglycemia.
Something off on this page? Send us feedback.
Develops the oral, gut-restricted SGLT1 inhibitor mizagliflozin for post-bariatric hypoglycemia and earlier-stage metabolic and gastrointestinal indications, funding research through capital rather than product sales and depending on an in-licensed compound across most of its pipeline.
Develops mizagliflozin, an oral, minimally absorbed SGLT1 inhibitor designed to alter post-meal glucose absorption and insulin and GIP secretion. The lead program targets post-bariatric hypoglycemia, with earlier plans for gastroparesis and GIP-dependent Cushing's syndrome; VGX-2857 is a preclinical weight-maintenance combination concept. There are no approved products or commercial operations.
Operates from Raleigh with worldwide mizagliflozin rights excluding Japan, Korea and Taiwan. The company relies on Kissei's license, outsourced manufacturing, contract research organizations, clinical sites and investigators. Development is financed by equity and debt capital rather than product sales, and most of the pipeline depends on mizagliflozin.
Company facts
No analyst consensus on record.
Not reported.
Not reported.
No dividends on record.
No ownership filings on record for this listing.
- Amylyx Pharmaceuticals
Phase 3 PBH challenger with once-daily injectable GLP-1 blockade.
- Fractyl Health
Pivotal post-GLP-1 weight-maintenance alternative using a one-time procedure.
- Eli Lilly
Large-scale GLP-1 maintenance option with Zepbound and oral Foundayo.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Vogenx | $32.10 | −1.05% | $446.4M | — | — | — | — |
| Amylyx Pharmaceuticals | $34.85 | +1.01% | $3.83B | — | — | — | — |
| Fractyl Health | $0.7077 | −0.03% | $112.1M | — | — | — | — |
| Eli Lilly | $1,165.80 | +0.55% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Median | 38.9 | 28.4 | 13.7 | +47.7% |